The Anti-CD138 Indatuximab Ravtansine Biosimilar (MAB-HDBS0014) is a highly specific monoclonal antibody designed for research involving CD138, a cell surface glycoprotein commonly expressed in plasma cells. This biosimilar antibody, derived from the innovative antibody-drug conjugate (ADC) platform, targets and delivers the cytotoxic agent ravtansine specifically to CD138-expressing cells, leading to targeted cell death.CD138, also known as syndecan-1, is a well-established marker for plasma cells and plays a crucial role in cell adhesion and migration. Its overexpression is frequently observed in multiple myeloma, a type of blood cancer that originates in plasma cells.
By targeting CD138 with the potent cytotoxic payload ravtansine, this biosimilar antibody offers a promising approach for the treatment of multiple myeloma and potentially other CD138-expressing malignancies.The Anti-CD138 Indatuximab Ravtansine Biosimilar (MAB-HDBS0014) opens up new possibilities for targeted therapy and personalized medicine in the field of oncology. Its high specificity and efficacy make it a valuable tool for studying CD138 biology, developing novel treatment strategies, and advancing precision medicine approaches for cancer patients.
Product Name:
Indatuximab (Anti-CD138) Biosimilar Antibody
Size:
100 ug
Product SKU:
HDBS0014
Target:
CD138
Host Species:
Chimeric
Reactivity:
Human
Recommended Dilution:
Flow Cyt 1:100
Antibody Type:
Monoclonal
Buffer:
Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions.
Storage & Shipping:
Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing).Lyophilized antibodies are shipped at ambient temperature.
Common Name:
BT-062, BT062, nBT062-DM4
Description:
Anti-CD138 (indatuximab biosimilar) mAb
Buffer:
Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions.
Format:
Powder
Applications
Flow Cyt
Antibody Isotype:
IgG4
Guarantee:
12 months from date of dispatch
Background:
Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
